The Oncology Institute, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 64.98 million compared to USD 52.28 million a year ago. Net loss was USD 2.67 million compared to USD 2.98 million a year ago. Basic loss per share from continuing operations was USD 0.03. Diluted loss per share from continuing operations was USD 0.17.
For the nine months, revenue was USD 181.06 million compared to USD 150.7 million a year ago. Net income was USD 11.16 million compared to net loss of USD 0.771 million a year ago. Basic earnings per share from continuing operations was USD 0.12. Diluted loss per share from continuing operations was USD 0.03.